Results 131 to 140 of about 455,569 (249)

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

open access: yesArthritis Care &Research, Volume 78, Issue 10, Page 1449-1466, October 2026.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci   +25 more
wiley   +1 more source

Short‐Chain Fatty Acids: Microbial Metabolites Driving Gut‐Eye Axis Signaling

open access: yesComprehensive Physiology, Volume 16, Issue 5, October 2026.
Short‐chain fatty acids generated by gut microbial fermentation link diet to ocular physiology via the gut–eye axis. Through systemic distribution, these metabolites regulate GPCR signaling, epigenetic pathways, inflammation, and angiogenesis, shaping retinal homeostasis and highlighting therapeutic potential in ocular vascular and inflammatory ...
Aleah J. Brokemond   +6 more
wiley   +1 more source

Mucosal‐Associated Invariant T Cells in Health and Disease

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao   +5 more
wiley   +1 more source

Subthreshold microsecond laser for proliferative diabetic retinopathy: a randomized pilot study

open access: yes, 2018
Mahima Jhingan,1 Abhilash Goud,1 Hari Kumar Peguda,1 Mitali Khodani,1 Jeffrey K Luttrull,2 Jay Chhablani1 1L V Prasad Eye Institute, Kallam Anji Reddy Campus, Hyderabad, India; 2Ventura County Retina Vitreous Medical Group, CA, USA Aim: To compare the ...
Jhingan M   +5 more
core  

Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines   +8 more
wiley   +1 more source

Elevated GDF15 in ocular fluids of patients with proliferative diabetic retinopathy. [PDF]

open access: yesFront Endocrinol (Lausanne)
Wang Z   +9 more
europepmc   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli   +3 more
wiley   +1 more source

Topographical Evaluation of Neovessels in Proliferative Diabetic Retinopathy by Using a Multimodal Imaging Approach. [PDF]

open access: yesJ Clin Med
Costanzo E   +6 more
europepmc   +1 more source

Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)—An International Phase 3 Clinical Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8812-8824, October 2026.
ABSTRACT Aims Attaining target glycaemia can be a challenge in Type 1 Diabetes (T1D) due to insulin‐induced weight gain. Adjunct therapy with modern glucose‐lowering agents developed for type 2 diabetes (T2D) has great potential but may be insufficiently efficacious and carries risks of hypoglycaemia and ketosis.
Joseph G. Timmons   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy